CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 102
- Registration Number
- NCT00044018
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธSt Vincent's Cancer Center, New York, New York, United States
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2002-06-27
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00040391
- Locations
- ๐บ๐ธ
Research Center, Milwaukee, Wisconsin, United States
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
Phase 2
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT00002127
- Locations
- ๐บ๐ธ
Marin County Specialty Clinic, Greenbrae, California, United States
๐บ๐ธGottlieb Med Group, Sherman Oaks, California, United States
๐บ๐ธGeorge Washington Univ Med Ctr, Washington, District of Columbia, United States
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
Not Applicable
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00002157
- Locations
- ๐บ๐ธ
Celgene Corp, Warren, New Jersey, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath